BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 21983055)

  • 1. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
    Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
    J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative combined with postoperative chemoembolization can improve survival in patients with hepatocellular carcinoma: a single-center study.
    Liu Y; Yang R
    J Vasc Interv Radiol; 2009 Apr; 20(4):472-83. PubMed ID: 19250841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?
    Shim JH; Park JW; Choi JI; Kim HB; Lee WJ; Kim CM
    J Vasc Interv Radiol; 2009 Feb; 20(2):209-16. PubMed ID: 19084432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization.
    Hong K; McBride JD; Georgiades CS; Reyes DK; Herman JM; Kamel IR; Geschwind JF
    J Vasc Interv Radiol; 2009 Mar; 20(3):360-7. PubMed ID: 19167245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoembolization in patients at high risk: results and complications.
    Kiely JM; Rilling WS; Touzios JG; Hieb RA; Franco J; Saeian K; Quebbeman EJ; Pitt HA
    J Vasc Interv Radiol; 2006 Jan; 17(1):47-53. PubMed ID: 16415132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
    Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
    Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
    Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
    Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma.
    Gunji T; Kawauchi N; Akahane M; Watanabe K; Kanamori H; Ohnishi S
    Int J Oncol; 2002 Aug; 21(2):427-32. PubMed ID: 12118341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study.
    Padia SA; Johnson GE; Horton KJ; Ingraham CR; Kogut MJ; Kwan S; Vaidya S; Monsky WL; Park JO; Bhattacharya R; Hippe DS; Harris WP
    J Vasc Interv Radiol; 2017 Jun; 28(6):777-785.e1. PubMed ID: 28365172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.
    Kothary N; Weintraub JL; Susman J; Rundback JH
    J Vasc Interv Radiol; 2007 Dec; 18(12):1517-26; quiz 1527. PubMed ID: 18057286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.